Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 6/2012

01-12-2012 | Erratum

Erratum to: Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma

Authors: Jason Konner, Rachel N. Grisham, Jae Park, Owen A. O’Connor, Gillian Cropp, Robert Johnson, Alison L. Hannah, Martee L. Hensley, Paul Sabbatini, Svetlana Mironov, Samuel Danishefsky, David Hyman, David R. Spriggs, Jakob Dupont, Carol Aghajanian

Published in: Investigational New Drugs | Issue 6/2012

Login to get access

Excerpt

Erratum to: Invest New Drugs …
Metadata
Title
Erratum to: Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma
Authors
Jason Konner
Rachel N. Grisham
Jae Park
Owen A. O’Connor
Gillian Cropp
Robert Johnson
Alison L. Hannah
Martee L. Hensley
Paul Sabbatini
Svetlana Mironov
Samuel Danishefsky
David Hyman
David R. Spriggs
Jakob Dupont
Carol Aghajanian
Publication date
01-12-2012
Publisher
Springer US
Published in
Investigational New Drugs / Issue 6/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-011-9780-8

Other articles of this Issue 6/2012

Investigational New Drugs 6/2012 Go to the issue

PRECLINICAL STUDIES

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models

SHORT REPORT

SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155

PRECLINICAL STUDIES

Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling

SHORT REPORT

Severe meningo-radiculo-nevritis associated with ipilimumab

PHASE I STUDIES

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors

PRECLINICAL STUDIES

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits